Long-term Results from an Open-label Extension Study of Atacicept for the Treatment of IgA Nephropathy

Explore the results of the ORIGIN Phase 2b study and open label extension in this video abstract

This video abstract was supported by Vera Therapeutics 

Key:

Complete
Failed
Available
Locked
Long-term Results from an Open-label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Open to view video.
Open to view video.
You must register to access.